Cosmos Health Inc COSM
NASDAQ · Amerika Birleşik Devletleri · Sağlık Teknolojisi
$0,4299+0,01 (+%2,16)
Piyasa kapalı· · USD · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Piyasa kapalı· · USD · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
By Brad Sorensen, CFA NASDAQ: COSM READ THE FULL COSM RESEARCH REPORT Cosmos Health (NASDAQ: COSM) has spent the past several years building what management describes as a vertically integrated healthcare platform spanning pharmaceutical manufacturing, distribution, proprietary brands, nutraceuticals, R&D, and telehealth. Two announcements released on September 28 and September 29 provide
* Record Q2 2026 revenue of over $15 million, an annualized run-rate of over $60 million, at wholly owned subsidiary CosmoFarm * Revenue up 4.3x under Cosmos Health ownership \- from ~$14 million in fiscal 2017, the last full year before acquisition, to an annualized run-rate of over $60 million; ~330% growth at a CAGR of approximately 18% * Successive record revenue years in 2023, 2024 and 2025, with 2026 expected to continue the trend, based on distribution volumes and performance to date * Ph
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
* Contract manufacturing pipeline surpasses $20 million in implied revenue at wholly owned subsidiary Cana Laboratories, representing over $18 million in implied gross profit across the life of agreements * Gross margins of over 90% \- among the highest-margin revenue streams in the Company, with raw materials largely supplied by clients * Record production pipeline of more than 32.7 million units, up approximately sixfold since mid-2024 and close to threefold since the start of this year, with
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.